AdultPediatricDosage Forms & Strengths Each tab/cap contains equal portions of the following: amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate tablet: Schedule II 5mg (1.25mg/1.25mg/1.25mg/1.25mg) 10mg (2.5mg/2.5mg/2.5mg/2.5mg) 20mg (5mg/5mg/5mg/5mg) 30mg (7.5mg/7.5mg/7.5mg/7.5mg) capsule, extended-release: Schedule II 5mg (1.25mg/1.25mg/1.25mg/1.25mg) (Adderall XR) 10mg (2.5mg/2.5mg/2.5mg/2.5mg) (Adderall XR) 12.5mg (3.125mg/3.125mg/3.125mg/3.125mg) (Mydayis) 15mg (3.75mg/3.75mg/3.75mg/3.75mg) (Adderall XR) 20mg (5mg/5mg/5mg/5mg) (Adderall XR) 25mg (6.25mg/6.25mg/6.25mg/6.25mg) (Adderall XR, Mydayis) 30mg (7.5mg/7.5mg/7.5mg/7.5mg) (Adderall XR) 37.5mg (9.375mg/9.375mg/9.375mg/9.375mg) (Mydayis) 50mg (12.5mg/12.5mg/12.5mg/12.5mg) (Mydayis) Attention Deficit Hyperactivity Disorder (ADHD) Tablet: 5 mg PO qDay initially; may increase by 5-10 mg/day qWeek; administer daily dose in 2-3 doses; not to exceed 40 mg/day Extended-release capsule Adderall XR 20 mg PO qAM initially or switching from another medication May increase by increments of 5-10 mg/week; not to exceed 60 mg/day Mydayis 18-55 years: 12.5 mg qAM initially May increase by increments of 12.5 mg/week; not to exceed 50 mg/day Note: 25 mg qAM may be considered as an initial dose for some patients Narcolepsy Amphetamine/dextroamphetamine 5-60 mg PO qDay; may increase by 10 mg/day qWeek No more than 60 mg given qDay or divided doses with intervals of 4-6 hr between doses Dosing Modifications Extended release Severe renal impairment (GFR 15 to <30 mL/min/1.73m²): Reduce recommended dose to 15 mg PO qDay ESRD (GFR < 15 ml/min/1.73m²): Not recommended Dosage Forms & Strengths Each tab/cap contains equal portions of the following: amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate tablet: Schedule II 5mg (1.25mg/1.25mg/1.25mg/1.25mg) 10mg (2.5mg/2.5mg/2.5mg/2.5mg) 20mg (5mg/5mg/5mg/5mg) 30mg (7.5mg/7.5mg/7.5mg/7.5mg) capsule, extended-release: Schedule II 5mg (1.25mg/1.25mg/1.25mg/1.25mg) (Adderall XR) 10mg (2.5mg/2.5mg/2.5mg/2.5mg) (Adderall XR) 12.5mg (3.125mg/3.125mg/3.125mg/3.125mg) (Mydayis) 15mg (3.75mg/3.75mg/3.75mg/3.75mg) (Adderall XR) 20mg (5mg/5mg/5mg/5mg) (Adderall XR) 25mg (6.25mg/6.25mg/6.25mg/6.25mg) (Adderall XR, Mydayis) 30mg (7.5mg/7.5mg/7.5mg/7.5mg) (Adderall XR) 37.5mg (9.375mg/9.375mg/9.375mg/9.375mg) (Mydayis) 50mg (12.5mg/12.5mg/12.5mg/12.5mg) (Mydayis) Attention Deficit Hyperactivity Disorder (ADHD) Tablet <3 years: Safety and efficacy not established Age 3-6 years: 2.5 mg/day; may increase by 2.5 mg qWeek; not to exceed 40 mg qDay or divided q8hr; use intervals of 4-6 hr between additional doses >6 years: 5 mg PO qDay or q12hr; may increase by 5 mg qWeek; not to exceed 40 mg qDay or divided q8hr; use intervals of 4-6 hr between additional doses Capsule, extended-release (Adderall XR) <6 years: Safety and efficacy not established ≥6 years to <13 years: 5-10 mg PO qAM initially; may increase by 5-10 mg/day qWeek; not to exceed 30 mg/day 13-17 years: 10 mg PO qAM initially; may increase to 20 mg/day after 1 week if symptoms not controlled; doses up to 60 mg/day have been used, but there is no evidence that higher doses increase effectiveness Mydayis <13 years: Safety and efficacy not established; younger children experienced higher plasma exposure than those aged ≥13 yr at the same dose, and experienced higher rates of adverse reactions, mainly insomnia and decreased appetite ≥13-17 years: 12.5 mg qAM initially May increase by increments of 12.5 mg/week; not to exceed 50 mg/day Narcolepsy <6 years: Safety and efficacy not established 6-12 years: 5mg/day PO initially in divided doses; may increase by 5 mg/day qWeek; not to exceed 60 mg qDay or divided doses with intervals of 4-6 hr between doses >12 years: 10 mg/day PO initially; may increase by 10 mg/day qWeek; not to exceed 60 mg given qDay or divided doses with intervals of 4-6 hr between doses Dosing Modifications Severe renal impairment <6 years: Not established 6-17 years: 5 mg once daily recommended; not to exceed 20 mg once daily for children 6 to 12 years of age End stage renal disease (GFR < 15 mL/min/1.73m²): Not recommended End stage renal disease < 15 mL/min/1.73m² Interaction CheckerEnter a drug name and amphetamine/dextroamphetamineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (10)iobenguane I 123dextroamphetamine decreases effects of iobenguane I 123 by receptor binding competition. Contraindicated. If clinically appropriate, discontinue drugs that compete for NE receptor sites for at least 5 half-lives; may cause false-negative imaging results.isocarboxazidisocarboxazid increases effects of dextroamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.linezolidlinezolid increases effects of dextroamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.phenelzinephenelzine increases effects of dextroamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.procarbazineprocarbazine increases effects of dextroamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.rasagilinerasagiline increases effects of dextroamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Coadministration is contraindicated during or within 14 days following the administration of MAOIs.safinamidedextroamphetamine, safinamide. Either increases toxicity of the other by serotonin levels. Contraindicated. Concomitant use could result in life-threatening serotonin syndrome.selegilineselegiline and dextroamphetamine both increase serotonin levels. Contraindicated. Amphetamines should not be administered during or within 14 days following the use of most MAOIs or drugs with MAO-inhibiting activityselegiline increases effects of dextroamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Coadministration is contraindicated during or within 14 days following the administration of MAOIs.selegiline transdermalselegiline transdermal increases effects of dextroamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.tranylcyprominetranylcypromine increases effects of dextroamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.Serious - Use Alternative (18)amitriptylineamitriptyline, dextroamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.amoxapineamoxapine, dextroamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.cabergolinecabergoline, dextroamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.clomipramineclomipramine, dextroamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.desfluranedesflurane increases toxicity of dextroamphetamine by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of V tach, HTN.desipraminedesipramine, dextroamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.desvenlafaxinedextroamphetamine and desvenlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.dihydroergotaminedihydroergotamine, dextroamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.dihydroergotamine intranasaldihydroergotamine intranasal, dextroamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.doxapramdoxapram increases effects of dextroamphetamine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive pressor effect.doxepindoxepin, dextroamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.ergoloid mesylatesergoloid mesylates, dextroamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.ergotamineergotamine, dextroamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.etherether increases toxicity of dextroamphetamine by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of V tach, HTN.imipramineimipramine, dextroamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.iobenguane I 131amphetamine will decrease the level or effect of iobenguane I 131 by Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose.dextroamphetamine will decrease the level or effect of iobenguane I 131 by Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose.isocarboxazidisocarboxazid and dextroamphetamine both increase serotonin levels. Avoid or Use Alternate Drug.ozanimodozanimod increases toxicity of amphetamine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use.Monitor Closely (200)5-HTP5-HTP and dextroamphetamine both increase serotonin levels. Use Caution/Monitor.acetazolamideacetazolamide will increase the level or effect of dextroamphetamine by passive renal tubular reabsorption - basic urine. Use Caution/Monitor.albuterolalbuterol and dextroamphetamine both decrease sedation. Use Caution/Monitor.albuterol and dextroamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.alfentanilalfentanil increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.almotriptanalmotriptan and dextroamphetamine both increase serotonin levels. Use Caution/Monitor.alprazolamalprazolam increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.aluminum hydroxidealuminum hydroxide will increase the level or effect of dextroamphetamine by passive renal tubular reabsorption - basic urine. Use Caution/Monitor.amitriptylineamitriptyline increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.amitriptyline and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.amitriptyline increases effects of dextroamphetamine by unknown mechanism. Use Caution/Monitor.ammonium chlorideammonium chloride decreases levels of dextroamphetamine by increasing renal clearance. Use Caution/Monitor.amobarbitalamobarbital increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.amoxapineamoxapine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.amoxapine and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.amoxapine increases effects of dextroamphetamine by unknown mechanism. Use Caution/Monitor.arformoterolarformoterol and dextroamphetamine both decrease sedation. Use Caution/Monitor.arformoterol and dextroamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.aripiprazolearipiprazole increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.armodafinilarmodafinil and dextroamphetamine both decrease sedation. Use Caution/Monitor.artemether/lumefantrineartemether/lumefantrine will increase the level or effect of dextroamphetamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.azelastineazelastine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.belladonna and opiumbelladonna and opium increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.benazeprildextroamphetamine decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor.benperidolbenperidol increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, amphetamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.benzhydrocodone/acetaminophen, dextroamphetamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.benzphetaminedextroamphetamine and benzphetamine both decrease sedation. Use Caution/Monitor.benzphetamine and dextroamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.buprenorphine, long-acting injectionamphetamine, buprenorphine, long-acting injection. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.bromocriptinebromocriptine, dextroamphetamine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach.brompheniraminebrompheniramine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.buprenorphine buccalbuprenorphine buccal increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.buprenorphine subdermal implantdextroamphetamine, buprenorphine subdermal implant. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.buprenorphine, long-acting injectiondextroamphetamine, buprenorphine, long-acting injection. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.bupropionbupropion will increase the level or effect of dextroamphetamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.dextroamphetamine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as